ATE356204T1 - Antisense-zusammensetzungen und verfahren zur behandlung von krebs - Google Patents
Antisense-zusammensetzungen und verfahren zur behandlung von krebsInfo
- Publication number
- ATE356204T1 ATE356204T1 AT00968807T AT00968807T ATE356204T1 AT E356204 T1 ATE356204 T1 AT E356204T1 AT 00968807 T AT00968807 T AT 00968807T AT 00968807 T AT00968807 T AT 00968807T AT E356204 T1 ATE356204 T1 AT E356204T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- treating cancer
- stem cells
- antisense compositions
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 abstract 4
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15834099P | 1999-10-07 | 1999-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356204T1 true ATE356204T1 (de) | 2007-03-15 |
Family
ID=22567684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00968807T ATE356204T1 (de) | 1999-10-07 | 2000-10-06 | Antisense-zusammensetzungen und verfahren zur behandlung von krebs |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1228202B1 (de) |
| JP (1) | JP2003511393A (de) |
| KR (1) | KR100695677B1 (de) |
| AT (1) | ATE356204T1 (de) |
| AU (1) | AU784358B2 (de) |
| CA (1) | CA2385220A1 (de) |
| DE (1) | DE60033840D1 (de) |
| WO (1) | WO2001025422A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1224261A1 (de) * | 1999-10-07 | 2002-07-24 | Avi Biopharma, Inc. | .hämatopoietische stammzellen behandelt mit c-myc-antisensmoleküle und dazugehörende verfahren |
| GB0118223D0 (en) * | 2001-07-26 | 2001-09-19 | Univ Sheffield | Stem loop RNA |
| WO2003064626A2 (en) | 2002-02-01 | 2003-08-07 | Sequitur, Inc. | Double-stranded oligonucleotides |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| US20040102390A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch3 expression |
| US20040101847A1 (en) * | 2002-11-22 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch2 expression |
| WO2005021783A2 (en) * | 2003-08-30 | 2005-03-10 | Adrian Merlo | New use of gain and loss of notch2 function in brain tumors and the new notch2 genetic alterations of the notch2 gene per se |
| AU2007356840B2 (en) * | 2007-07-25 | 2013-07-18 | Alma Mater Studiorum - Universita Di Bologna | Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| EP2571987B1 (de) | 2010-05-21 | 2017-03-01 | Peptimed, Inc. | Reagenzien zur behandlung von krebs |
| SG190088A1 (en) | 2010-11-01 | 2013-06-28 | Peptimed Inc | Compositions of a peptide targeting system for treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101600A (en) * | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
-
2000
- 2000-10-06 EP EP00968807A patent/EP1228202B1/de not_active Expired - Lifetime
- 2000-10-06 JP JP2001528575A patent/JP2003511393A/ja active Pending
- 2000-10-06 KR KR1020027004476A patent/KR100695677B1/ko not_active Expired - Fee Related
- 2000-10-06 AU AU78668/00A patent/AU784358B2/en not_active Ceased
- 2000-10-06 AT AT00968807T patent/ATE356204T1/de not_active IP Right Cessation
- 2000-10-06 WO PCT/US2000/027636 patent/WO2001025422A2/en not_active Ceased
- 2000-10-06 DE DE60033840T patent/DE60033840D1/de not_active Expired - Lifetime
- 2000-10-06 CA CA002385220A patent/CA2385220A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020064793A (ko) | 2002-08-09 |
| AU7866800A (en) | 2001-05-10 |
| JP2003511393A (ja) | 2003-03-25 |
| EP1228202B1 (de) | 2007-03-07 |
| EP1228202A2 (de) | 2002-08-07 |
| WO2001025422A3 (en) | 2001-08-23 |
| KR100695677B1 (ko) | 2007-03-15 |
| WO2001025422A2 (en) | 2001-04-12 |
| CA2385220A1 (en) | 2001-04-12 |
| AU784358B2 (en) | 2006-03-16 |
| DE60033840D1 (de) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE265219T1 (de) | Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten | |
| DK1082410T3 (da) | Humane CD45 - og/eller fibroblast mesenchymale stamceller | |
| ATE446776T1 (de) | Zusammensetzung zur gefässbeschichtung | |
| DE69937888D1 (de) | Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen | |
| GB9807639D0 (en) | Anti-inflammatory agents | |
| BR0011197A (pt) | Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura | |
| MXPA03011890A (es) | Polinucleotidos de defensina y metodos de uso. | |
| ATE356204T1 (de) | Antisense-zusammensetzungen und verfahren zur behandlung von krebs | |
| DE60319398D1 (de) | Verfahren zur herstellung einer pureezusammensetzung enthaltend eine stabilisierte fruchtmarkzusammensetzung | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| WO2003057849A3 (en) | Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats | |
| TR200103634T2 (tr) | Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi. | |
| DE69931050D1 (de) | Brassica-transformation durch teilchenbeschuss | |
| DE69902523D1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| ATE348876T1 (de) | Verfahren zur vermehrung von natürlichen killerzellen | |
| DE60316959D1 (de) | Haarbehandlungszusammensetzung | |
| ATE524198T1 (de) | Verfahren zur einführung von genen in säugetiere | |
| PT1147088E (pt) | 6-arilfenantridinas com actividade inibitoria da pde-iv | |
| WO2002067652A3 (en) | Novel mutilple shoot proliferation and regeneration system for plants | |
| 张宝红 et al. | Anther culture and plant regeneration of cotton (Gossypium klotzschianum Anderss) | |
| AU8371501A (en) | Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes | |
| PT793503E (pt) | Uso do factor de crescimento dos hepatocitos para induzir a proliferacao e diferenciacao de celulas henatopoieticas | |
| DE3879575D1 (de) | Alpha-carotin zur wachstumshemmung von krebszellen. | |
| DK0416572T3 (da) | RNA med endoribonucleasevirkning mod mRNA fra modningsgener, dens fremstilling af den anvendelse i planter | |
| Khojasteh et al. | The effect of deproteinized bovine bone mineral on saos-2 cell proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |